Compile Data Set for Download or QSAR
maximum 50k data
Found 27 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase JAK3' and Ligand = 'BDBM333122'
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.180nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.280nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent